Lumosa Therapeutics Co., Ltd.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Taipei Taiwan (2001)

Organization Overview

First Clinical Trial
2012
NCT02468128
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Lumosa Phase 1 unit | Lumosa Therapeutics | Lumosa Therapeutics Co., Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Ischemia (Phase 2)

Pruritus (Phase 2)

Stroke (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 8